PolymarketCerradoComprobar disponibilidadSin KYC2% de comisiónDatos de resolución verificadosCalibración aceptableEste mercado se resolvió: Yes
Resuelto: 28 jun 2026, 23:21
Resolución verificada por el proveedor
CoinRithm tiene evidencia del ganador y del momento de liquidación respaldada por el proveedor para este mercado.
Resultado Ganador
Yes
A 7 días
—
A 24 horas
—
Probabilidad implícita actual
Sí 100%+0.0pt
Calidad del mercado
≤49 / 100
Baja calidadVolumen 24h
4,8 mil €
Liquidez
—
Liquidez desconocidaCompra / Venta
99.9% / 100.0%
Spread
0.1 pt
Spread estrechoCambio 7d
+26.9 pts
Datos de mercado
Actualizado hace 64 días
Desactualizado4 jun 26, 19:5430 jun 26, 0:00
Cronología de Probabilidad
No0%
Yes100%
100%
0%
Reglas
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
